Literature DB >> 11296133

Models of chronic myeloid leukemia.

R A Van Etten1.   

Abstract

Models of chronic myeloid leukemia (CML) have proven invaluable for furthering our understanding of the molecular pathophysiology of this disease. Xenotransplantation of primary human CML cells into immunodeficient mice allows investigation into the nature of the most primitive repopulating cells in this leukemia, but the system is limited by variability and difficulty with experimental manipulation. Accordingly, a large effort has been invested in developing models of CML through expression of the BCR/ABL oncogene in the hematopoietic system of laboratory mice. Despite numerous attempts, an accurate transgenic mouse model of CML has not been produced, possibly because of the toxicity of BCR/ABL. Conditional transgenic mice are a promising new approach to this problem. A more successful strategy is retroviral transduction of BCR/ABL into mouse bone marrow in vitro, followed by transplantation into syngeneic or immunodeficient recipient mice. Recipients of marrow transduced with p210 BCR/ABL develop a fatal myeloproliferative illness that closely resembles human CML. This model is being used to define the signaling pathways required for leukemogenesis by BCR/ABL, and for developing new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11296133     DOI: 10.1007/s11912-001-0055-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  49 in total

1.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

2.  Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice.

Authors:  M Bhatia; J C Wang; U Kapp; D Bonnet; J E Dick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

3.  Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.

Authors:  A W Gross; X Zhang; R Ren
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

4.  Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5.

Authors:  V Sexl; R Piekorz; R Moriggl; J Rohrer; M P Brown; K D Bunting; K Rothammer; M F Roussel; J N Ihle
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

5.  High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase.

Authors:  J C Wang; T Lapidot; J D Cashman; M Doedens; L Addy; D R Sutherland; R Nayar; P Laraya; M Minden; A Keating; A C Eaves; C J Eaves; J E Dick
Journal:  Blood       Date:  1998-04-01       Impact factor: 22.113

6.  A model of Ph' positive chronic myeloid leukemia-blast crisis cell line growth in immunodeficient SCID mice.

Authors:  T Skórski; M Nieborowska-Skórska; B Calabretta
Journal:  Folia Histochem Cytobiol       Date:  1992       Impact factor: 1.698

7.  BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.

Authors:  J W Voncken; V Kaartinen; P K Pattengale; W T Germeraad; J Groffen; N Heisterkamp
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113

8.  Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis.

Authors:  C Sirard; T Lapidot; J Vormoor; J D Cashman; M Doedens; B Murdoch; N Jamal; H Messner; L Addey; M Minden; P Laraya; A Keating; A Eaves; P M Lansdorp; C J Eaves; J E Dick
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

9.  Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice.

Authors:  H Honda; T Fujii; M Takatoku; H Mano; O N Witte; Y Yazaki; H Hirai
Journal:  Blood       Date:  1995-05-15       Impact factor: 22.113

10.  bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

Authors:  A G Elefanty; I K Hariharan; S Cory
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

View more
  11 in total

1.  Production of replication-defective retrovirus by transient transfection of 293T cells.

Authors:  L Cristina Gavrilescu; Richard A Van Etten
Journal:  J Vis Exp       Date:  2007-12-04       Impact factor: 1.355

2.  Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia.

Authors:  Mio Yamamoto-Sugitani; Junya Kuroda; Eishi Ashihara; Hisao Nagoshi; Tsutomu Kobayashi; Yosuke Matsumoto; Nana Sasaki; Yuji Shimura; Miki Kiyota; Ryuko Nakayama; Kenichi Akaji; Tomohiko Taki; Nobuhiko Uoshima; Yutaka Kobayashi; Shigeo Horiike; Taira Maekawa; Masafumi Taniwaki
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

3.  Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling.

Authors:  Ming Yan; Jiann-Kae Luo; Kenneth J Ritchie; Ikuya Sakai; Kasuto Takeuchi; Ruibao Ren; Dong-Er Zhang
Journal:  Blood       Date:  2007-03-20       Impact factor: 22.113

Review 4.  The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.

Authors:  Richard A Van Etten; Steffen Koschmieder; Francois Delhommeau; Danilo Perrotti; Tessa Holyoake; Animesh Pardanani; Ruben Mesa; Tony Green; Amr R Ibrahim; Tariq Mughal; Robert Peter Gale; John Goldman
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

5.  Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia.

Authors:  Andrea Hoelbl; Christian Schuster; Boris Kovacic; Bingmei Zhu; Mark Wickre; Maria A Hoelzl; Sabine Fajmann; Florian Grebien; Wolfgang Warsch; Gabriele Stengl; Lothar Hennighausen; Valeria Poli; Hartmut Beug; Richard Moriggl; Veronika Sexl
Journal:  EMBO Mol Med       Date:  2010-03       Impact factor: 12.137

6.  A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.

Authors:  Ryan P Million; Nari Harakawa; Sergei Roumiantsev; Lyuba Varticovski; Richard A Van Etten
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

7.  Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.

Authors:  Zainab Jagani; Keli Song; Jeffery L Kutok; M Rajan Dewar; Armelle Melet; Tanya Santos; Alexandra Grassian; Saghi Ghaffari; Catherine Wu; Heather Yeckes-Rodin; Heather Yeckes Rodin; Ruibao Ren; Kenneth Miller; Roya Khosravi-Far
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

Review 8.  Aberrant cytokine signaling in leukemia.

Authors:  R A Van Etten
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

9.  Leukemia stem cells in a genetically defined murine model of blast-crisis CML.

Authors:  Sarah J Neering; Timothy Bushnell; Selcuk Sozer; John Ashton; Randall M Rossi; Pin-Yi Wang; Deborah R Bell; David Heinrich; Andrea Bottaro; Craig T Jordan
Journal:  Blood       Date:  2007-06-29       Impact factor: 22.113

Review 10.  Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia.

Authors:  Kalubai Vari Khajapeer; Rajasekaran Baskaran
Journal:  Leuk Res Treatment       Date:  2015-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.